Vertex's Next Steps Closely Watched Following Merck-Roche Deal On Victrelis

All eyes are on Vertex Pharmaceuticals and whether it will change course and seek a marketing partner following the May 17 announcement that Merck and Roche will co-promote Merck’s newly approved hepatitis C drug Victrelis (boceprevir).

More from Archive

More from Pink Sheet